Lymphoma classification and incidence
| . | CD137L−/− . | CD27;CD137L−/− . | WT . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Age, mo | 6-9 | 10-12 | 13-16 | 6-9 | 10-12 | 13-16 | 6-9 | 10-12 | 13-16 |
| Total, n | 28 | 30 | 31 | 53 | 39 | 18 | 6 | 9 | 14 |
| Preneoplastic | 3 | 2 | 1 | 10 | 10 | 3 | – | – | 3 |
| Early stage FL | 1 | 7 | 6 | 4 | 11 | 6 | – | – | 1 |
| Late stage FL | – | 5 | 10 | 4 | 5 | 5 | – | – | 1 |
| DLBCL | 1 | – | 2 | – | – | 1 | – | – | – |
| SBCL | – | – | 4 | 1 | – | – | – | – | – |
| PCT-A | – | – | – | – | 2 | 1 | – | – | – |
| Lymphoma incidence, % (no.) | 7 (2/28) | 40 (12/30) | 71 (22/31) | 17 (9/53) | 46 (18/39) | 72 (13/18) | 0 (0/6) | 0 (0/9) | 14 (2/14) |
| . | CD137L−/− . | CD27;CD137L−/− . | WT . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Age, mo | 6-9 | 10-12 | 13-16 | 6-9 | 10-12 | 13-16 | 6-9 | 10-12 | 13-16 |
| Total, n | 28 | 30 | 31 | 53 | 39 | 18 | 6 | 9 | 14 |
| Preneoplastic | 3 | 2 | 1 | 10 | 10 | 3 | – | – | 3 |
| Early stage FL | 1 | 7 | 6 | 4 | 11 | 6 | – | – | 1 |
| Late stage FL | – | 5 | 10 | 4 | 5 | 5 | – | – | 1 |
| DLBCL | 1 | – | 2 | – | – | 1 | – | – | – |
| SBCL | – | – | 4 | 1 | – | – | – | – | – |
| PCT-A | – | – | – | – | 2 | 1 | – | – | – |
| Lymphoma incidence, % (no.) | 7 (2/28) | 40 (12/30) | 71 (22/31) | 17 (9/53) | 46 (18/39) | 72 (13/18) | 0 (0/6) | 0 (0/9) | 14 (2/14) |
B-cell malignancies observed in CD137L−/−, CD27;CD137L−/−, and wild-type (WT) mice per age group. Preneoplastic lesions, early- and late-stage GC-derived B-cell lymphoma were defined as outlined in “Results.” Classification as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), small B-cell lymphoma (SBCL), or anaplastic plasmacytoma (PCT-A) was performed according to the Bethesda proposals.27